Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Solidaki E, Chatzi L, Bitsios P, Markatzi I, Plana E, Castro F. Work-related and psychological determinants of multisite musculoskeletal pain. Scand J Work Environ Health. 2010 Jan;36(1):54-61.
Yang J, Eickbush TH. RNA-induced changes in the activity of the endonuclease encoded by the R2 retrotransposable element. Mol Cell Biol. 1998 Jun;18(6):3455-65.
Rothman KJ. Cancer occurrence among workers exposed to acrylonitrile. Scand J Work Environ Health. 1994 Jan 1;20(5):313-21. doi: 10.5271/sjweh.1391
Lanes SF, Rothman KJ, Dreyer NA, Soden KJ. Mortality update of cellulose fiber production workers. Scand J Work Environ Health. 1993 Jan 1;19(6):426-8.
Walker AM, Cohen AJ, Loughlin JE, Rothman KJ, Defonso LR. Mortality from cancer of the colon or rectum among workers exposed to acrylate and methyl methacrylate. Scand J Work Environ Health. 1991 Jan 1;17(1):7-19.
Lanes SF, Cohen A, Rothman KJ, Dreyer NA, Soden KJ. Mortality of cellulose fiber production workers. Scand J Work Environ Health. 1990 Aug 1;16(4):247-51.